106results about How to "Increase proliferation rate" patented technology

The invention provides an OCTS-CAR technique-based OCTS-CAR double-targeting chimeric antigen receptor, a coding gene and a recombinant expression vector and establishment and application of the OCTS-CAR double-targeting chimeric antigen receptor, the coding gene and the recombinant expression vector. The OCTS-CAR double-targeting chimeric antigen receptor includes a CD8 leader membrane receptor signal peptide, a double-antigen binding region, a CD8 Hinge chimeric receptor gemel, a CD8 transmembrane chimeric receptor transmembrane region, a CD28 chimeric receptor co-stimulatory factor, a CD134 chimeric receptor co-stimulatory factor and a TCR chimeric receptor T cell activating domain which are connected sequentially and in series, wherein the double-antigen binding region comprises heavy-chain VH and light-chain VL, connected in a certain mode, of two single-chain antibodies, an antibody Inner-Linker and an Inter-Linker between single-chain antibodies, and the two single-chain antibodies are formed by combining any two of a BCMA single-chain antibody, a CD319 single-chain antibody, a CD38 single-chain antibody, a PDL1 single-chain antibody and a CD123 single-chain antibody; in addition, the invention further provides a gene encoding the OCTS-CAR double-targeting chimeric antigen receptor, the recombinant expression vector and an establishment method and application of the gene encoding the OCTS-CAR double-targeting chimeric antigen receptor and the recombinant expression vector.

The invention relates to a novel method for quickly repairing injured anaerobic ammonium oxidation bacterium groups. The novel method is characterized in that homoserine lactone signal molecules C6-HSL (acyl-homoserine lactone) are added into the injured anaerobic ammonium oxidation bacterium groups to improve the activity of anaerobic ammonium oxidation bacteria, increase the reproduction rate of the anaerobic ammonium oxidation bacteria and relieve inactivation and death causing effects of external inhibitors on the anaerobic ammonia oxidation bacteria; owing to added homoserine lactone signal molecules C8-HSL, the reproduction rate of the anaerobic ammonium oxidation bacterium groups can be increased, and repair for the injured anaerobic ammonium oxidation bacterium groups can be accelerated. The novel method has the advantages that the novel method is simple and feasible, effects are obvious, the application range is wide, the bottleneck problem of inactivation or death of anaerobic ammonium oxidation bacteria due to the fact that the anaerobic ammonium oxidation bacteria can be easily inhibited during actual application is solved, and the novel method can be used for implementing relevant anaerobic ammonium oxidation processes and efficiently biologically denitrifying sewage.

The present invention relates to a human mesenchymal stem cell serum-free medium, the main components of the human mesenchymal stem cell serum-free medium include a basal medium and an additive; the mesenchymal stem cell serum-free medium has a clear composition and no animal-derived component. A mesenchymal stem cell product produced by the human mesenchymal stem cell serum-free medium is used clinically without causing anaphylactic reaction; and the serum-free medium is simple in preparation method, does not require any special equipment, and is easy to be mass-produced; and mesenchymal stemcells produced by the human mesenchymal stem cell serum-free medium have good cell homogeneity and high proliferation rate. After repeated passages, detection results of cell surface markers are up to standard, and the cells still have good capability of differentiation into osteoblasts, adipocytes and chondrocytes.

The invention relates to a preparation method of a carbon nanotube/titania nanotube bio-composite coat material. The preparation method comprises the following steps: preparing an aligned titania nanotube array coat having a caliber of 50-100nm on the surface of a pure titanium plate through utilizing an anodization process; and uniformly depositing functionalized multi-wall carbon nanotubes on a titanium matrix with the surface having a titania nanotube array through utilizing an electrophoretic deposition process. The reproduction rate of human osteoblast on the surface of the composite coat prepared in the invention is higher than the reproduction rate of the human osteoblast on the pure titanium plate having a smooth surface.

The invention relates to a medical titanium surface composite coating and a preparation method thereof. The surface of a medical titanium material is a manganese doped titanium oxide modified layer which is firmly combined with a titanium base material, wherein the manganese doped titanium oxide modified layer is of a dense porous structure obtained by performing micro-arc oxidation treatment on the surface of the base material and consists of anatase titanium oxide, rutile titanium oxide and a manganese element.

The invention discloses an OCTS (One CAR (Chimeric Antigen Receptor) with two ScFvs (Single-chain variable Fragments)) technique based CAR-T (Chimeric Antigen Receptor-T cell immunotherapy) therapeutic vector for glioblastoma. The OCTS technique based CAR-T therapeutic vector comprises a lentiviral skeleton plasmid, a human EF1 [alpha] promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and a PDL1 single-chain antibody, wherein the OCTS chimeric receptor structural domain comprises a CD8 leader chimeric receptor signal peptide (SEQ ID NO. 15), a PDL1 single-chain antibody light chain VL (SEQ ID NO. 16), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO. 17), an EGFRvIII single-chain antibody light chain VL (SEQ ID NO. 18), an EGFRvIII single-chain antibody heavy chain VH (SEQ ID NO. 19), an antibody Inner-Linker (SEQ ID NO. 20), a single-chain antibody Inter-Linker (SEQ ID NO. 21), a CD8 Hinge chimeric receptor linker (SEQ ID NO. 22), a CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO. 23), a TCR (T Cell Receptor) chimeric receptor T cell activation domain (SEQ ID NO. 26) and a chimeric receptor co-stimulator domain. In addition, the invention also discloses a construction method of the vector and application of the vector to the preparation of a medicine for treating the glioblastoma.

The invention belongs to the field of cell culture, and particularly relates to a cell culture method. The cell culture method comprises the following steps that 1, a peripheral blood mononuclear cell is separated; 2, the peripheral blood mononuclear cell separated in the first step is added into a plasma-containing activated culture medium to activate NK cells; 3, a proliferation culture medium is added into the peripheral blood mononuclear cell which is cultured for 10 days in the second step to promote proliferation of the NK cells. According to the cell culture method, the technical defect that the amplified cell volume is low when the NK cells are subjected to in vitro expansion can be effectively overcome.

The invention discloses a CAR-T (Chimeric antigen receptor T-cell immunotherapy) therapeutic vector for T lymphocytic leukemia. The therapeutic vector comprises a lentivirus skeleton plasmid, a humanEF1 alpha promoter and a CAR chimeric receptor domain, wherein the CAR chimeric receptor domain contains CD8 leader chimeric acceptor signal peptide, a CD7 single-chain antibody light chain VL, a CD7single-chain antibody heavy chain VH, an antibody inner hinge UCLinker, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane region, a TCR chimeric receptor T cellactivation domain and a chimeric receptor co-stimulatory factor region. The invention further discloses a construction method of the vector and an application of the vector in preparation of a drug for treating T lymphocytic leukemia.

The invention discloses a marker used for in-vivo tracing and manual removal of CAR-T cells. The marker comprises a trace-linker 1 with a sequence as shown in SEQ ID No. 18, a trace-linker 2 with a sequence as shown in SEQ ID No. 19 and a trace-linker 3 with a sequence as shown in SEQ ID No. 19. The invention also discloses a CAR-T therapy vector including the marker and a construction method thereof. Moreover, the invention further discloses application of the marker to preparation of the CAR-T therapy vector and drugs used for treating triple-negative breast cancer. The marker provided by the invention can realize controllable in-vivo tracing, in-vitro separation and manual removal of CAR-T cells without influence on the tumor killing effect of the CAR-T cells, so the security of CAR-T cell therapy is greatly improved, and a powerful pool can be provided for deeper analysis of the process of CAR-T cell therapy. The vector provided by the invention can express a targeting chimeric antigen receptor of CD117 in human T lymphocytes, guides and activates killing effect of T lymphocytes on CD117 positive cells, and is applicable to treatment of triple-negative breast cancer in clinical practice.

A method of cell-fusion is provided, the method comprising fusing cells in a medium comprising a liquid composition having a liquid and nanostructures, each of the nanostructures comprising a core material of a nanometric size surrounded by an envelope of ordered fluid molecules, the core material and the envelope of ordered fluid molecules being in a steady physical state, thereby fusing cells. Compositions and articles of manufacture are also provided for generating monoclonal antibodies and culturing eukaryotic cells.

The invention discloses a method for realizing rapid proliferation of anaerobic ammonium oxidation bacteria. In the method for realizing rapid proliferation of anaerobic ammonium oxidation bacteria, based on the maximum electron transfer ability of anaerobic ammonium oxidation bacteria, the anaerobic ammonium oxidation is started in combination of an MBR reactor; and by inoculating the mixed sludge consisting of 90% of nitration sludge and 10% of anaerobic granular sludge, the sludge retention time is gradually shortened, the maximum specific growth rate of the anaerobic ammonium oxidation bacteria is increased, and rapid proliferation of anaerobic ammonium oxidation bacteria is realized. In the invention, based on the characteristics of long start time of anaerobic ammonium oxidation and slow sludge increase, the MBR is combined with the anaerobic ammonium oxidation, the best sludge source is inoculated, and the novel efficient nitrogen removal technology can be applied to practical production in a large scale as much as possible.

TOLL Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

The invention relates to a detoxification and rapid propagation method of snow white strawberries. The detoxification and rapid propagation method comprises the following steps: S1, explant selectionand surface cleaning, namely selecting 2-4cm stem tips of snow white strawberry grape stems as explants, and carrying out surface cleaning; S2, sterilization, namely placing the surface-cleaned explants on a workbench for sterilization; S3, induced cultivation, namely picking 0.5mm stem tips of the explants by using a dissecting needle under an anatomical lens, and inoculating the 0.5mm stem tipson an induced culture medium for induced culture for 50-60 days to obtain young seedlings of the snow white strawberries; S4, virus detection and seedling selection, namely carrying out virus detection on the young seedlings of the snow white strawberries by using a virus kit, and selecting the young seedlings, reaching the standard, of the snow white strawberries; S5, subculture multiplication culture, namely transplanting the young seedlings, reaching the standard, of the snow white strawberries into a multiplication culture medium, and carrying out subculture once every 30 days for 5-6 times; and S6, rooting culture, namely transplanting young seedlings with the plant heights being 3-5cm of the snow white strawberries into a rooting culture medium for culture for 20-30 days to obtain snow white strawberry plants.

The invention belongs to the field of biotechnology, and relates to an establishing method of Hertwig's epithelial root sheath cell lines HERS-H1 and HERS-C2 of SD rats and applications of the Hertwig's epithelial root sheath cell lines HERS-H1 and HERS-C2 of SD rats in tooth regeneration. The establishing method and the applications are characterized in that the Hertwig's epithelial root sheath cell line HERS-H1 is assigned with the accession number of CCTCC NO.C2017249, and the Hertwig's epithelial root sheath cell line HERS-C2 is assigned with the accession number of CCTCC NO.C2017250. According to the method and the applications, for the cell lines, the features of the primary Hertwig's epithelial root sheath cells in the tooth development process are reserved, passage to 50 generations is available at least, and the multiplication rate is greatly improved compared with that of the primary cells. The establishing method is easy to operate, and high in stability and repeatability.

The invention discloses a culture method of cymbidium, aiming at solving the problems that when the cymbidium is bred by a tissue culture technique at present, mutation is inevitably produced, so that the seedling quality is influenced, and the breeding speed of protocorm-like bodies is limited. The culture method comprises the following steps: inducing the protocorm-like bodies by bud apical meristem, carrying out subculture multiplication of the protocorm-like bodies, carrying out differentiation on the protocorm-like bodies to produce adventitious buds, and carrying out strong seedling culture on the adventitious buds to obtain seedlings. After the culture method is used, the problem of mutation in the seedling production of the cymbidium can be effectively solved, the occurrence of mutation is reduced, the value-added ratio is increased, more than half of the subculture multiplication time is shortened, and the multiplication rate of the protocorm-like bodies is improved. The test proves that the value-added rate of the protocorm-like bodies is increased by 80-120%, the mutational rate is reduced by 5-9%, and the problem of contradiction between the value-added rate and the mutational rate of the protocorm-like bodies of the cymbidium can be effectively solved. The culture method has important significance for the rapid breeding and industrial large-scale production of the seedlings of the cymbidium, and has better market prospects and application values.

The invention provides a human umbilical cord mesenchymal stem cell serum-free medium characterized by comprising an alpha-MEM basal medium and further comprising the following components by final concentration: 1-20 mM of glutamine, 1-20 mM of HEPEs, 10-100 muM of putrescine, 0.1-10 muM of transferrin, 10-400 muM of vitamin C, 1-10 muM of recombinant insulin, 1-20 nM of progesterone, 10-200 nM ofcortisol, 1-20 mg/mL of human serum albumin, 1-10 ng/mL of basic fibroblast growth factor, beta 11-10 ng/mL of transforming growth factor and 1-50 mg/mL of spirulina fast-soluble proteoglycan. The human umbilical cord mesenchymal stem cell serum-free medium can significantly improve the proliferation rate and the adherence performance of human umbilical cord mesenchymal stem cells, is beneficialto the proliferation of the human umbilical cord mesenchymal stem cells and the maintenance of stem cell characteristics, and has the potential of adipogenic osteogenic induced differentiation. The medium is simple, clear and stable, does not contain any serum components, overcomes the risk of heterologous protein contamination and pathogenic microorganisms, and has high safety.

The invention discloses an OCTS technology-based prostatic cancer CAR-T therapy vector which comprises a lentivirus framework plasmid, a human EP1alpha promoter (SEQ ID NO.14), an OCTS chimeric receptor structure domain and a PDL1 single-chain antibody, wherein the OCTS chimeric receptor structure domain comprises A CD8 leader chimeric receptor signal peptide (SEQ ID NO.15), a PSMA single-chain antibody light chain VL (SEQ ID NO.16), a PSMA single-chain antibody heavy chain VH (SEQ ID NO.17), a PDL1 single-chain antibody light chain VL (SEQ ID NO.18), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO.19), an antibody Inner-Linker (SEQ ID NO.20), a single-chain antibody Inter-Linker (SEQ ID NO.21), a CD8 Hinge chimeric receptor hinge (SED ID NO.22), a CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO.23), a TCR chimeric receptor T cell activation domain (SEQ ID NO.26) and a chimeric receptor co-stimulus factor domain. In addition, the invention further discloses a construction method of the vector and an application of the vector in preparation of drugs for treating a prostatic cancer.

The invention discloses a method for cultivating oil-producing microorganisms adopting jerusalem artichoke as raw materials. The method comprises the following steps of preparing a seed culture medium, proliferating and cultivating thallus, preparing an oil-producing culture medium, culturing thallus oil in an accumulated mode, extracting oil-producing microorganism oil and the like. Inulin is adopted as the raw materials for preparing the culture medium, the cost is low, and the method is applicable to large-scale industrial application; according to characteristics of a jerusalem artichoke hydrolysate and different processing modes, the content of nutrient elements is adjusted, the culture technology for phosphorus-limiting/sulfur-control combined two-stage culture of oil-producing microorganisms is developed, the thallus proliferation speed and the oil accumulation rate of the oil-producing microorganisms are remarkably improved, and the oil yield is remarkably improved. Due to the application, the biodiesel oil raw material sources are enlarged, the production period can be remarkably shortened, the production cost is lowered, and the production efficiency is improved.